EyePoint Pharmaceuticals (EYPT) Misses Q3 EPS by 8c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.85), $0.08 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $966 thousand versus the consensus estimate of $3.46 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
• Deere shares climb as fiscal Q3 earnings and revenue top estimates
• Exchange Bank declares Q3 dividend, CEO to retire in 2027